On March 19, 2026, the FDA approved Wegovy HD — a 7.2mg once-weekly semaglutide injection that produces roughly 21% mean weight loss. That's triple the standard Wegovy dose. And it changes the competitive landscape of GLP-1 weight-loss treatment significantly.
If you're currently on Wegovy 2.4mg and feel like you've plateaued, or if you've been looking at tirzepatide (Zepbound/Mounjaro) because the weight loss numbers are better — this approval is directly relevant to you.
What is Wegovy HD?
Wegovy HD is semaglutide 7.2mg injected once weekly. It uses the same active ingredient as standard Wegovy (2.4mg), Ozempic, and the new Wegovy pill — just at a substantially higher dose.
It's approved for adults with obesity (BMI ≥30) or overweight (BMI ≥27 with at least one weight-related condition) who have already tolerated the 2.4mg dose for at least four weeks and need additional weight reduction. You can't start directly on 7.2mg — you escalate through the standard doses first.
The approval came through the FDA's Commissioner's National Priority Voucher programme, which fast-tracked the review in just 54 days after filing. Novo Nordisk plans to launch the single-dose pen in US pharmacies in April 2026.
The trial data
The STEP UP trial was a 72-week, randomised, double-blind, placebo-controlled study comparing semaglutide 7.2mg against semaglutide 2.4mg and placebo in approximately 1,400 adults with obesity (Wharton et al., 2025).
The results are striking.
Mean weight loss at 72 weeks:
- Semaglutide 7.2mg: 20.7%
- Semaglutide 2.4mg: approximately 15%
- Placebo: approximately 2%
Percentage achieving ≥25% weight loss:
- Semaglutide 7.2mg: approximately one in three participants
- Semaglutide 2.4mg: substantially fewer
For context, the SURMOUNT-5 head-to-head trial showed tirzepatide 15mg (Zepbound) produced 20.2% weight loss versus semaglutide 2.4mg at 13.7% (Aronne et al., 2025). With 7.2mg semaglutide producing 20.7%, the semaglutide platform has essentially matched tirzepatide's best results.
The STEP UP T2D trial, in adults with both obesity and type 2 diabetes, showed 14.1% mean weight loss with 7.2mg and comparable blood sugar improvements to lower doses (Lingvay et al., 2025).
Why this matters for the semaglutide vs tirzepatide debate
Until this approval, the narrative was clear: tirzepatide produces more weight loss than semaglutide. The SURMOUNT-5 head-to-head trial proved it.
Wegovy HD complicates that narrative. At the highest available doses:
- Semaglutide 7.2mg: 20.7% weight loss
- Tirzepatide 15mg: 20.2% weight loss
These numbers are close enough that the practical difference for most patients is negligible. The choice between molecules becomes less about raw efficacy and more about other factors — cost, formulation preferences, additional indications, and individual tolerance.
This is especially significant because semaglutide's core patent expired on March 20, 2026. Generic semaglutide is on the horizon. Tirzepatide remains patent-protected through the 2030s. When generic semaglutide arrives, the cost argument for semaglutide — at comparable efficacy — becomes very powerful.
Side effects at the higher dose
The safety profile at 7.2mg was broadly consistent with what's known about semaglutide at lower doses. Gastrointestinal side effects (nausea, vomiting, diarrhoea, constipation) remain the most common, occurring primarily during dose escalation.
One new finding: dysaesthesia — altered skin sensation described as sensitivity, pain, or burning — was reported more frequently at 7.2mg than at lower doses. This is a new signal not previously seen with standard-dose semaglutide. The FDA noted it generally resolves on its own or with dose reduction, but flagged it as requiring further investigation.
This isn't a reason to avoid the medication, but it's something to be aware of and discuss with your doctor if you're considering the step up to 7.2mg.
Who is this for?
Wegovy HD isn't for everyone starting GLP-1 treatment. It's specifically designed as a step-up option for people who:
- Have been on Wegovy 2.4mg for at least four weeks
- Are tolerating the medication well
- Need additional weight reduction beyond what 2.4mg provides
- Have discussed with their doctor whether the higher dose is appropriate
If you're happy with your results on 2.4mg, there's no pressure to increase. If you've plateaued and want more, this gives you a clear next step within the same medication family — rather than switching to an entirely different molecule.
The bigger picture: Wegovy's 2026 portfolio
Wegovy now has the broadest product line of any GLP-1 weight-loss medication:
- Wegovy pill (25mg daily): For people who prefer oral medication. $149-$299/month cash pay.
- Wegovy injection (2.4mg weekly): The established standard dose.
- Wegovy HD injection (7.2mg weekly): The new high dose for maximum results.
Plus unique indications no other weight-loss GLP-1 has:
- Cardiovascular risk reduction (SELECT trial: 20% MACE reduction) (Lincoff et al., 2023)
- MASH/fatty liver disease
- Chronic kidney disease
Novo Nordisk has also submitted CagriSema (semaglutide + cagrilintide, combining GLP-1 and amylin agonism) for FDA approval — which could push the semaglutide platform even further.
What to ask your doctor
If you're currently on Wegovy or Ozempic and this sounds relevant, here are the key questions:
- Am I a candidate for the 7.2mg dose based on my current response and tolerance?
- What additional monitoring, if any, would you recommend at the higher dose?
- Given the dysaesthesia reports, what should I watch for?
- How does this compare cost-wise to my current treatment through my insurance?
Wegovy HD launches in April 2026. If you're interested, start the conversation with your healthcare provider now.
Key Studies & References
We base this guide on the strongest available peer-reviewed research so you can see exactly where the information comes from.
-
Wharton et al. (2025) — The STEP UP trial demonstrating semaglutide 7.2mg achieved 20.7% mean weight loss at 72 weeks, with one-third of participants losing 25% or more. The pivotal study behind Wegovy HD's FDA approval. Read the full study
-
Lingvay et al. (2025) — The STEP UP T2D trial evaluating semaglutide 7.2mg in adults with obesity and type 2 diabetes, showing 14.1% mean weight loss with a safety profile consistent with prior semaglutide data. Read the full study
-
Aronne et al. (2025) — The SURMOUNT-5 head-to-head trial comparing tirzepatide 15mg vs semaglutide 2.4mg, providing the context against which Wegovy HD's 20.7% result should be measured. Read the full study
-
Lincoff et al. (2023) — The SELECT trial demonstrating semaglutide's 20% reduction in major cardiovascular events, an indication unique to the Wegovy platform. Read the full study